Work

PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.07.021

Authors: C. Mathias, M. Reck, M. Hellmann, S. Ramalingam, J. Brahmer, K. O'Byrne, P. Bhagavatheeswaran, F. Nathan, H. Borghaei, L. Paz-Ares

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Memorial Sloan Kettering Cancer Center, Emory University, Winship Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Princess Alexandra Hospital, Bristol-Myers Squibb (United States), Fox Chase Cancer Center, Universidad Complutense de Madrid

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2891591763

FWCI:

Cites:

Cited by:

Related to: 10